GlassScriptPhysician profile
Ramesh G Patel
NPI 1912044520
$111,528.98
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $18K · 2021: $17K · 2022: $25K · 2023: $16K · 2024: $7,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $4,361 · Education: $111 · Travel and Lodging: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,459.75 |
| Food and Beverage | $4,360.80 |
| Education | $111.49 |
| Travel and Lodging | $109.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $66,495.03 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $26,928.93 | 2019-2024 | Aristada, Aristada Initio, Lybalvi |
| Sunovion Pharmaceuticals INC. | $8,614.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $4,835.31 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,884.24 | 2019-2024 | Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $771.35 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $546.05 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $279.89 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $77.58 | 2024 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.00 | 2022 | |
| Lundbeck LLC | $38.03 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $18.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.